InFACT – the International Forum for Acute Care Trialists, is a global collaboration of acute care clinicians and researchers building capacity in ICUs around the world during COVID-19.
InFACT was established by independent investigator-led clinical research groups and academic research consortia around the world to provide a forum to build international collaboration.
Have a read through our First Ten Years programmatic report here.
As part of a WHO-led international collaborative response to the COVID-19 outbreak, a working group on clinical characterisation and management developed a minimum set of outcome measures for studies of the emerging outbreak.
The International Forum for Acute Care Trialists (InFACT) was launched in 2008 as a network of investigator-led clinical research groups and academic institutions whose focus is the optimal care of critically ill children and adults. Our members include 33 organizations from around the world, spanning a spectrum of research foci, structural formality, and experience.
InFACT is a network of investigator-led clinical research groups and academic institutions whose focus is the optimal care of critically ill children and adults. Our members now include 37 organizations from around the world, spanning a spectrum of research foci, structural formality, and experience.
InFACT is actively engaged in building partnerships with organizations and regional research groups.
Over 70 countries engaged and represented.
At InFACT, we focus on thematic ares of research. We call these our working groups.
The ICU is an important venue for the acquisition and transmission of antimicrobial resistance (AMR). It also provides a unique perspective on the risk factors for the development of ICU-acquired infection. International collaboration provides unique and important opportunities to understand the epidemiology of ICU-acquired infection and antimicrobial resistance, and to evaluate strategies to reduce these.
One of the most important priorities for InFACT is to build research capacity outside of North America and Europe, and to empower groups in Central and South America, Africa, and Asia to assume their legitimate leadership roles in framing an international research agenda for the best care of critically ill patients.
The 2009 H1N1 influenza pandemic confronted critical care researchers with a challenge: how to mobilize a research response to a rapidly emerging and incompletely understood international threat, and how to communicate the data emerging from any studies to decision-makers who were charged with leading a global clinical response.
Clinical research is only as impactful as the measures used to understand its consequences. Outcome measurement in critical illness is chaotic and poorly standardized, with the result that it is challenging to pool the results of multiple trials.
Dr. Madiha Hashmi, Karachi, Pakistan
